Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LIPO |
---|---|---|
09:32 ET | 3656 | 2.85 |
09:33 ET | 349 | 2.9 |
09:42 ET | 100 | 2.93 |
09:44 ET | 3013 | 2.8817 |
09:46 ET | 300 | 2.915 |
09:48 ET | 370 | 2.93 |
09:50 ET | 1250 | 2.9101 |
09:51 ET | 2033 | 2.9053 |
09:55 ET | 300 | 2.96 |
10:00 ET | 922 | 2.89 |
10:04 ET | 200 | 2.95 |
10:06 ET | 300 | 2.925 |
10:08 ET | 100 | 2.95 |
10:09 ET | 100 | 2.91 |
10:11 ET | 2500 | 2.9001 |
10:20 ET | 1009 | 2.84 |
10:22 ET | 300 | 2.8396 |
10:24 ET | 149 | 2.8 |
10:26 ET | 1376 | 2.75 |
10:27 ET | 3437 | 2.8 |
10:38 ET | 250 | 2.7658 |
10:54 ET | 2000 | 2.7834 |
10:58 ET | 555 | 2.78 |
11:02 ET | 299 | 2.79 |
11:05 ET | 300 | 2.8 |
11:14 ET | 185 | 2.8059 |
11:20 ET | 100 | 2.81 |
11:30 ET | 130 | 2.8101 |
11:34 ET | 200 | 2.83 |
11:36 ET | 1599 | 2.85 |
11:38 ET | 182 | 2.85 |
11:56 ET | 100 | 2.835 |
12:03 ET | 100 | 2.85 |
12:08 ET | 200 | 2.84 |
12:17 ET | 193 | 2.8366 |
12:24 ET | 262 | 2.84 |
12:26 ET | 637 | 2.8395 |
12:50 ET | 561 | 2.83 |
12:53 ET | 922 | 2.78 |
01:08 ET | 300 | 2.81 |
01:33 ET | 743 | 2.8099 |
01:44 ET | 100 | 2.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Lipella Pharmaceuticals Inc | 3.2M | -0.6x | --- |
Biodexa Pharmaceuticals PLC | 2.7M | 0.0x | --- |
Aptorum Group Ltd | 4.2M | -0.8x | --- |
Cyclacel Pharmaceuticals Inc | 2.2M | 0.0x | --- |
Palisade Bio Inc | 3.2M | -0.2x | --- |
Aditxt Inc | 3.0M | 0.0x | --- |
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2M |
---|---|
Revenue (TTM) | $507.2K |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4.95 |
Book Value | $4.16 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -839.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.